Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4476083 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL8950475 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4468251 | 0.87 | CASP3 (0.60) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL30423183 | 0.85 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4581609 | 0.85 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL29443002 | 0.85 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4581604 | 0.85 | CASP3 (0.51) | CASP3CA12CA9GLSDRD3 | |
| SCHEMBL4579077 | 0.79 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL21901972 | 0.79 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 | |
| SCHEMBL461209 | 0.79 | CASP3 (0.53) | CASP3CA12CA9GLSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0635023-B1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2002-02-06 | — | — | EP | disclosed |
| US-5719271-A | HYBRIDS; GENETIC ENGINEERING | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-17 | — | — | US | disclosed |
| US-5543507-A | BONDING STRANDS OR ONE STRAND AT DIFFERENT SITES; RNA MIMICS FIXED IN SPATIAL CONFORMATION; NUCLEASE RESISTANT MIMICS OF BINDING RECEPTORS FOR NUCLEIC ACID-BINDING PROTEINS; 5-LIPOXYGENASE INHIBITORS; DIAGNOSIS; ANALYZING | ISIS PHARMACEUTICALS, INC. (US) | 1996-08-06 | — | — | US | disclosed |
| EP-0635023-A4 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES. | ISIS PHARMACEUTICALS INC (US) | 1996-03-20 | — | — | EP | disclosed |
| EP-0635023-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-01-25 | — | — | EP | disclosed |
| WO-1993018052-A1 | COVALENTLY CROSS-LINKED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |